Cipla Uncorks Peptide Injectables Pipeline, Eyes Partnering For Monkeypox
Executive Summary
Cipla readies scale up in peptide injectables with five filings in the US and gears for upcoming high value launches for generic versions of Advair, Revlimid and Abraxane. The company is also exploring partnering opportunities for monkeypox.
You may also be interested in...
Cipla Stays Upbeat On Advair Generic With ‘Superior’ Cost Position, Derisks Abraxane
Generic Revlimid and lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.
Cipla Stays Upbeat On Advair Generic With ‘Superior’ Cost Position, Derisks Abraxane
Generic Revlimid, lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.
Dr Reddy’s Gears For Generic Revlimid Run In US, Quarterly ‘Blips’ Aside
Quarterly ups and down notwithstanding, Dr Reddy’s signals continuing US launch momentum, with its generic Revlimid, for which the Indian firm claims exclusivity for two strengths, set to hit the market next month. “Low competition” assets, especially injectables, also continue to be on the deal-making radar in the US.